A new data analysis tool developed by researchers at The University of Texas MD Anderson Cancer Center incorporates a user-friendly, natural-language interface to allow biomedical researchers without specialized expertise in bioinformatics or programming languages to conduct intuitive analysis of large datasets.
The open-access, artificial intelligence (AI)-driven program, called DrBioRight, was created to lower barriers for...
The University of Texas MD Anderson Cancer Center and Taiho Pharmaceutical Co., Ltd., today announced a three-year strategic collaboration...
The University of Texas MD Anderson Cancer Center has awarded Monica Johnson, M.H.A., C.P.X.P., the Julie and Ben Rogers Award for Excellence...
ABSTRACT: 1257O
In a Phase I clinical trial for patients with advanced solid cancers marked by KRAS G12C mutations, the KRASG12C inhibitor sotorasib (AMG 510) resulted in manageable toxicities and durable clinical benefits. Results from the trial were published today in the New England Journal of Medicine and data from the lung cancer cohort also were presented at the European Society for Medical Oncology (ESMO) Virtual Congress...
New preclinical research from The University of Texas MD Anderson Cancer Center and BridgeBio Pharma, Inc. affiliate Navire Pharma, Inc...
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center suggest that a combination of ipilimumab...
The University of Texas MD Anderson Cancer Center and Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co....
The University of Texas MD Anderson Cancer Center and Xencor, Inc. today announced a strategic collaboration to study investigational...